Revive Therapeutics Ltd (RVVTF)

[PennyWorld]

Yes, it makes perfect sense to change the endpoint. This risk is it's a moving target. In the case of rlftf they discovered that due to the evolving/improving SOC (standard of care) in hospitals, that it became harder to compete with SOC over time. So the FDA agreed to let them move their endpoint out from 30 days to 60 days. Which was still not enough to compete with the ever-improving SOC. Two+ years ago, before SOC evolved, the EUA would have been a slam dunk for Relief (and possibly for Revive too).

The key (that many folks miss) is these drugs are being compared to SOC in the Control Group. As SOC evolves and improves, relatively speaking the benefits of the drug diminishes over time. Relief even has before and after xrays (anecdotal evidence) demonstrating clear and obvious COVID improvement....however that was 2+ years ago before SOC evolved. As they say.... slow you blow, snooze you lose (unfortunately). So the million dollar question here is... how will Bucillamine compare to today's version of SOC. JMHO